{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:14:48Z","timestamp":1784394888434,"version":"3.55.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":727,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1093\/annonc\/mdx487","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T19:10:44Z","timestamp":1508267444000},"page":"2741-2746","source":"Crossref","is-referenced-by-count":29,"title":["A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy"],"prefix":"10.1016","volume":"28","author":[{"given":"K.","family":"Fizazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ulys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sengel\u00f8v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ladoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Thiery-Vuillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Flechon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Dumez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Matouskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Penel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Liutkauskiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Stachurski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Baton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Germann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Daugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx487_bb0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.urolonc.2014.10.009","article-title":"Immunotherapy for castration-resistant prostate cancer: progress and new paradigms","volume":"33","author":"Quinn","year":"2015","journal-title":"Urol Oncol"},{"issue":"2 Suppl 1","key":"10.1093\/annonc\/mdx487_bb0015","first-page":"98","article-title":"Emerging therapies in castration resistant prostate cancer","volume":"21","author":"Thoreson","year":"2014","journal-title":"Can J Urol"},{"key":"10.1093\/annonc\/mdx487_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-013-2321-8","article-title":"Mechanisms of action of tasquinimod on the tumour microenvironment","volume":"73","author":"Raymond","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdx487_bb0025","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.1158\/1078-0432.CCR-13-1581","article-title":"Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer","volume":"19","author":"Armstrong","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx487_bb0030","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1673-8527(09)60061-8","article-title":"Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis","volume":"37","author":"Ye","year":"2010","journal-title":"J Genet Genomics"},{"key":"10.1093\/annonc\/mdx487_bb0035","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2011.35.6295","article-title":"Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer","volume":"29","author":"Pili","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx487_bb0040","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/CCO.0000000000000110","article-title":"Maintenance therapy in ovarian cancer","volume":"26","author":"Khalique","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"10.1093\/annonc\/mdx487_bb0045","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/bjc.2013.472","article-title":"Baseline tumour measurements predict survival in advanced non-small cell lung cancer","volume":"109","author":"Gerber","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdx487_bb0050","series-title":"A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC)","author":"MA","year":"2015"},{"key":"10.1093\/annonc\/mdx487_bb0055","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2016.66.9697","article-title":"Phase III, randomized, double-blind, placebo-controlled study of tasquinimod in men with metastatic castrate-resistant prostate cancer","volume":"34","author":"Sternberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx487_bb0060","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jsbmb.2012.01.001","article-title":"Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys","volume":"129","author":"Yamaoka","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1093\/annonc\/mdx487_bb0065","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/pros.23236","article-title":"Orteronel switch maintenance therapy in metastatic castration resistant prostate cancer after first-line docetaxel: a multicenter, randomized, double-blind, placebo-controlled trial (SAKK 08\/11)","volume":"76","author":"Cathomas","year":"2016","journal-title":"Prostate"},{"key":"10.1093\/annonc\/mdx487_bb0070","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1634\/theoncologist.2015-0220","article-title":"Temsirolimus maintenance therapy after docetaxel induction in castration-resistant prostate cancer","volume":"20","author":"Emmenegger","year":"2015","journal-title":"Oncologist"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341934606X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341934606X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/11\/2741\/21556169\/mdx487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:07:03Z","timestamp":1624694823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341934606X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S092375341934606X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx487","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}